Cantor Fitzgerald Forecasts FATE FY2026 Earnings

Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Fate Therapeutics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek expects that the biopharmaceutical company will post earnings per share of ($0.73) for the year. The consensus estimate for Fate Therapeutics' current full-year earnings is ($1.63) per share.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.07. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%. The company had revenue of $1.63 million for the quarter, compared to analysts' expectations of $1.18 million.

Other equities analysts have also recently issued reports about the company. Wells Fargo & Company cut their target price on Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating on the stock in a report on Thursday, March 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Fate Therapeutics in a research note on Thursday. Wedbush restated a "neutral" rating and issued a $5.00 target price on shares of Fate Therapeutics in a report on Thursday, March 6th. Barclays dropped their price target on shares of Fate Therapeutics from $10.00 to $2.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 14th. Finally, Robert W. Baird decreased their price objective on Fate Therapeutics from $5.00 to $4.00 and set a "neutral" rating for the company in a report on Wednesday, May 14th. Eight equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $4.14.

Fate Therapeutics Stock Down 8.9%

NASDAQ:FATE traded down $0.13 on Tuesday, hitting $1.28. The stock had a trading volume of 2,427,036 shares, compared to its average volume of 2,252,891. The company has a market cap of $146.12 million, a PE ratio of -0.77 and a beta of 2.23. Fate Therapeutics has a 52 week low of $0.66 and a 52 week high of $5.92. The business's fifty day moving average is $1.20 and its 200 day moving average is $1.37.

Hedge Funds Weigh In On Fate Therapeutics

Institutional investors have recently modified their holdings of the business. American Century Companies Inc. lifted its holdings in Fate Therapeutics by 6.6% during the fourth quarter. American Century Companies Inc. now owns 197,704 shares of the biopharmaceutical company's stock worth $326,000 after acquiring an additional 12,295 shares during the period. SG Americas Securities LLC increased its position in shares of Fate Therapeutics by 30.6% during the 4th quarter. SG Americas Securities LLC now owns 44,874 shares of the biopharmaceutical company's stock valued at $74,000 after purchasing an additional 10,511 shares during the last quarter. Hsbc Holdings PLC raised its stake in shares of Fate Therapeutics by 22.0% during the 4th quarter. Hsbc Holdings PLC now owns 109,422 shares of the biopharmaceutical company's stock worth $179,000 after purchasing an additional 19,706 shares during the period. Millennium Management LLC boosted its holdings in shares of Fate Therapeutics by 28.9% in the 4th quarter. Millennium Management LLC now owns 413,192 shares of the biopharmaceutical company's stock worth $682,000 after buying an additional 92,576 shares during the last quarter. Finally, Squarepoint Ops LLC grew its position in Fate Therapeutics by 154.2% during the fourth quarter. Squarepoint Ops LLC now owns 34,295 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 20,805 shares during the period. 97.54% of the stock is owned by institutional investors.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.